150 related articles for article (PubMed ID: 1081933)
41. Immunological characterization of Hodgkin's and non-Hodgkin's lymphoma patients with high antibody titers against Epstein-Barr virus-associated antigens.
Masucci G; Mellstedt H; Masucci MG; Szigeti R; Ernberg I; Björkholm M; Tsukuda K; Henle G; Henle W; Pearson G
Cancer Res; 1984 Mar; 44(3):1288-300. PubMed ID: 6318984
[TBL] [Abstract][Full Text] [Related]
42. Prognostic significance of circulating cytotoxic lymphocytes against autologous tumors in patients with bladder cancer.
Mizutani Y; Okada Y; Terachi T; Yoshida O
J Urol; 1996 Mar; 155(3):888-92; discussion 892-4. PubMed ID: 8583600
[TBL] [Abstract][Full Text] [Related]
43. Nodular lymphocyte predominance type of Hodgkin's disease is a germinal center lymphoma.
Timens W; Visser L; Poppema S
Lab Invest; 1986 Apr; 54(4):457-61. PubMed ID: 3083157
[TBL] [Abstract][Full Text] [Related]
44. Lymphocyte function in patients with Hodgkin's disease.
Rühl H; Vogt W; Rühl U
G Batteriol Virol Immunol; 1975; 68(1-6):3-16. PubMed ID: 128484
[TBL] [Abstract][Full Text] [Related]
45. Heterogeneity of O6-alkylguanine-DNA alkyltransferase activity in peripheral blood lymphocytes: relationship between this activity in lymphocytes and in lymphoblastoid lines from normal controls and from patients with Hodgkin's disease or non-Hodgkin's lymphoma.
Sagher D; Karrison T; Schwartz JL; Larson RA; Strauss B
Cancer Res; 1989 Oct; 49(19):5339-44. PubMed ID: 2548719
[TBL] [Abstract][Full Text] [Related]
46. PHA dose dependent defect in lymphocyte stimulation and E-rosette-forming cells in untreated Hodgkin's disease.
Land JM; Litwin J; Bigel P; Oberling F; Mayer S
Acta Haematol Pol; 1977; 8(2):131-4. PubMed ID: 329629
[TBL] [Abstract][Full Text] [Related]
47. Lymphocyte populations of non-scleronodular Hodgkin's disease subtypes in different stages of lymphocyte depletion. An immunophenotypic and quantitative study.
Valente G; Ferrara P; Stramignoni A
Virchows Arch B Cell Pathol Incl Mol Pathol; 1990; 58(4):289-94. PubMed ID: 1970692
[TBL] [Abstract][Full Text] [Related]
48. Antibody-dependent direct cytotoxicity of human lymphocytes. I. Studies on peripheral blood lymphocytes and sera of patients with systemic lupus erythematosus.
Scheinberg MA; Cathcart ES
Clin Exp Immunol; 1976 May; 24(2):317-22. PubMed ID: 1084243
[TBL] [Abstract][Full Text] [Related]
49. Increased number of functionally defective large granular lymphocytes in lymphoma patients.
Muhonen T; Teerenhovi L; Saksela E
Nat Immun Cell Growth Regul; 1987; 6(2):57-64. PubMed ID: 3600676
[TBL] [Abstract][Full Text] [Related]
50. Cellular interactions in the proliferative response of human circulating lymphocytes to PHA-analysis of the impaired response in old age.
Duchateau J; Delespesse G; Gausset P; Govaerts A
Acta Endocrinol Suppl (Copenh); 1976; 205():35-47. PubMed ID: 1087095
[TBL] [Abstract][Full Text] [Related]
51. Levamisole in the treatment of Hodgkin's disease.
Berényi E; Kávai M; Szabolcsi M; Szegedi G
Acta Med Acad Sci Hung; 1979; 36(2):177-85. PubMed ID: 317549
[TBL] [Abstract][Full Text] [Related]
52. Cytotoxicity tests against cultured human lung cancer cells with autologous lymphocytes activated in vitro by mitomycin C-treated tumor monolayers in the presence of T-cell growth factor.
Kimura H; Yamaguchi Y; Kadoyama C; Sato N; Fujisawa T
Jpn J Clin Oncol; 1983 Mar; 13(1):3-13. PubMed ID: 6300483
[TBL] [Abstract][Full Text] [Related]
53. [Hodgkin's disease--immunological aspects].
Plat M; Frank KH; Fleischer J; Plat U; Koslowski R
Allerg Immunol (Leipz); 1988; 34(3):139-58. PubMed ID: 3057835
[TBL] [Abstract][Full Text] [Related]
54. In vitro studies on IgG-mediated lymphocyte cytotoxicity in chronic active liver disease.
Kawanishi H
Gastroenterology; 1977 Sep; 73(3):549-55. PubMed ID: 892355
[TBL] [Abstract][Full Text] [Related]
55. [Immunological aspects of Hodgkin's disease].
Bianchini E
Minerva Med; 1975 Feb; 66(8):365-70. PubMed ID: 1078722
[TBL] [Abstract][Full Text] [Related]
56. [Immune profile in patients with Hodgkin's disease in long-term remission after cytostatic chemotherapy].
Nagel GA; Pietra CD; Hartmann D; Rosenthal M; Albrecht R; Obrist R; Obrecht P
Schweiz Med Wochenschr; 1979 Jan; 109(2):45-51. PubMed ID: 311514
[TBL] [Abstract][Full Text] [Related]
57. [Persisting deficiency of cell mediated immunity in Hodgkin's disease in complete remission (author's transl)].
Lang JM; Bigel P; Giron C; Faradji A; Oberling F; Mayer S
Nouv Presse Med; 1979 Nov; 8(44):3629-32. PubMed ID: 316521
[TBL] [Abstract][Full Text] [Related]
58. Antibody-dependent and phytohaemagglutinin-induced lymphocyte cytotoxicity in systemic sclerosis.
Wright JK; Hughes P; Rowell NR; Sneddon IB
Clin Exp Immunol; 1979 Apr; 36(1):175-82. PubMed ID: 466860
[TBL] [Abstract][Full Text] [Related]
59. In vitro lymphocyte dysfunction in Hodgkin's disease.
Graze PR; Perlin E; Royston I
J Natl Cancer Inst; 1976 Feb; 56(2):239-43. PubMed ID: 130496
[TBL] [Abstract][Full Text] [Related]
60. Prostaglandin-producing suppressor cells in Hodgkin's disease.
Goodwin JS; Messner RP; Bankhurst AD; Peake GT; Saiki JH; Williams RC
N Engl J Med; 1977 Nov; 297(18):963-8. PubMed ID: 409950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
